Focal Adhesion Kinase Inhibition As A Therapeutic Strategy In Differentiated Thyroid Cancer

e13556 Background: Thyroid cancer, themost common endocrine malignancy, can be curable with resection of low stage tumors, but new treatments are needed for advanced differentiated cancers with radioiodine resistance. Focal Adhesion Kinase (FAK), a tyrosine kinase involved in protein-protein interactions regulating crucial cellular functions, is upregulated in thyroid cancer, and is a drug target along with its autophosphorylation site Y397. Clinical trials are ongoing for FAK inhibitors PF04554878 and GSK2256098. 1,2,4,5-Benzenetetraamine tetrahydrochloride (Y15), a small molecule FAK scaffolding inhibitor targeting the Y397 autophosphorylation site, and TAE226, a FAK/Insulin-like Growth Factor-1 Receptor inhibitor are in preclinical studies . In this report, we compared the effects of these FAK inhibitors on thyroid cancer cell lines. Methods: Four human thyroid cancer cell lines were cultured in vitro: K1, BCPAP, TPC1 derived from papillary thyroid carcinoma, and TT derived from medullary thyroid carci...